UNSPSC 51162708: Domiodol

This classification denotes a mucolytic agent with the molecular formula C5H9IO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) C1PXF8V06N, chemically known as 1,3-dioxolane-4-methanol, 2-(iodomethyl)-, (e,z)- but more generally known as domiodol, which bears US NIH Compound Identifier 43814. European Medicines Agency schedules Domiodol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06355MIG. The term DOMIODOL is an International Non-Proprietary Name.

UNSPSC 51162708 Domiodol, a Commodity code, covers pharmaceutical products and drug-related supplies that state and local governments purchase for public health and emergency response programs. The recent solicitations show state and local buyers acquiring naloxone (an opioid-overdose reversal medication), safe drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products through competitive bidding and cooperative purchasing vehicles. Issuing bodies include county health departments, state procurement offices administering multistate cooperative agreements, and participating municipalities within those alliances. The work involves product supply, quarterly or ongoing delivery to designated government facilities, compliance with FDA and Drug Supply Chain Security Act requirements, and adherence to current Good Manufacturing Practices standards.

Geographic activity centers on Florida and Minnesota, with multistate cooperative reach. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, with a response deadline of July 26, 2023 (note: date discrepancy in source); vendors must cover shipping and delivery costs and maintain workers' compensation, commercial general liability, and professional liability insurance. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities including Oregon, with proposals due March 26, 2026; the contract requires vendors to work through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), certify cGMP compliance, maintain $5 million commercial general liability insurance, and accept a 3 percent administrative fee, with pricing weighted at 75 percent of evaluation criteria and contract awards effective July 1, 2026.